Behshad Sheldon

Behshad Sheldon is a board member at Camurus and was previously with Cerecor Inc., Braeburn Pharmaceuticals, and Otsuka Pharmaceuticals. Sheldon has experience in global and US marketing, early development strategy, corporate communications, corporate planning, and stakeholder management.

At Otsuka Pharmaceuticals, Sheldon was a key driver in the partner selection and finalization of the Nov 11, 2011 landmark agreement between Otsuka Pharmaceutical Co Ltd and Lundbeck on Abilify IM depot, brexpiprazole and 3 Lundbeck quids. Sheldon also developed the oncology franchise at Otsuka through the acquisition of Busulfex (BMT prep) and co-promotion agreement of Sprycel (CML) with BMS while extending and solidifying the CNS agreement with BMS.

Sheldon was successful in the 2009 launch of Samsca (tolvaptan, vasopression antagonist for hyponatremia), a first-in-class product with significant market development needs. The hospital product was expected to reach >$100M in 2012 (third full year on market), originally forecasted to reach $35M at peak.

Behshad Sheldon has a Bachelor of Science in Neuroscience from the University of Rochester.